Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold

Sandhya Manohar, Samih H. Nasr, Nelson Leung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose of review: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. Recent findings: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN. Recovery of renal function is related to the speed and degree of the serum FLC reduction. Recently, two randomized trials using high cutoff dialyzer for the removal of serum FLC produced different results in terms of renal recovery. Summary: FLC plays a key role in the development and resolution of LCCN. Future therapies will aim to rapidly reduce its concentration or interrupt its interaction with Tamm-Horsfall protein.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - May 3 2018

Fingerprint

Light
Uromodulin
Immunoglobulin Light Chains
Kidney
Recovery of Function
Serum
Multiple Myeloma
Acute Kidney Injury
Urine

Keywords

  • Acute kidney injury
  • Cast nephropathy
  • Light chains
  • Multiple myeloma
  • Myeloma kidney
  • Plasma cell dyscrasia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Light Chain Cast Nephropathy : Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold. / Manohar, Sandhya; Nasr, Samih H.; Leung, Nelson.

In: Current Hematologic Malignancy Reports, 03.05.2018, p. 1-7.

Research output: Contribution to journalArticle

@article{b26d45db6c974828a2dbd7e95901b594,
title = "Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold",
abstract = "Purpose of review: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. Recent findings: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN. Recovery of renal function is related to the speed and degree of the serum FLC reduction. Recently, two randomized trials using high cutoff dialyzer for the removal of serum FLC produced different results in terms of renal recovery. Summary: FLC plays a key role in the development and resolution of LCCN. Future therapies will aim to rapidly reduce its concentration or interrupt its interaction with Tamm-Horsfall protein.",
keywords = "Acute kidney injury, Cast nephropathy, Light chains, Multiple myeloma, Myeloma kidney, Plasma cell dyscrasia",
author = "Sandhya Manohar and Nasr, {Samih H.} and Nelson Leung",
year = "2018",
month = "5",
day = "3",
doi = "10.1007/s11899-018-0451-0",
language = "English (US)",
pages = "1--7",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Light Chain Cast Nephropathy

T2 - Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold

AU - Manohar, Sandhya

AU - Nasr, Samih H.

AU - Leung, Nelson

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Purpose of review: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. Recent findings: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN. Recovery of renal function is related to the speed and degree of the serum FLC reduction. Recently, two randomized trials using high cutoff dialyzer for the removal of serum FLC produced different results in terms of renal recovery. Summary: FLC plays a key role in the development and resolution of LCCN. Future therapies will aim to rapidly reduce its concentration or interrupt its interaction with Tamm-Horsfall protein.

AB - Purpose of review: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. Recent findings: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN. Recovery of renal function is related to the speed and degree of the serum FLC reduction. Recently, two randomized trials using high cutoff dialyzer for the removal of serum FLC produced different results in terms of renal recovery. Summary: FLC plays a key role in the development and resolution of LCCN. Future therapies will aim to rapidly reduce its concentration or interrupt its interaction with Tamm-Horsfall protein.

KW - Acute kidney injury

KW - Cast nephropathy

KW - Light chains

KW - Multiple myeloma

KW - Myeloma kidney

KW - Plasma cell dyscrasia

UR - http://www.scopus.com/inward/record.url?scp=85046440783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046440783&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0451-0

DO - 10.1007/s11899-018-0451-0

M3 - Article

AN - SCOPUS:85046440783

SP - 1

EP - 7

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -